Secreted Phospholipase A2-VII Recombinant Protein | PLA2G7 recombinant protein
Recombinant Human Secreted Phospholipase A2-VII HEK
Sterile Filtered colorless solution.
Introduction: PLA2G7 is a secreted enzyme which catalyzes the degradation of platelet-activating factor to biologically inactive products. The PLA2G7 enzyme is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. In the blood, PLA2G7 goes mainly with LDL and less than 20% is coupled with HDL. PLA2G7 is implicated in the development of atherosclerosis and is also a marker for cardiac disease. PLA2G7 might have a major physiologic effect in the presence of inflammatory bodily responses.PLA2G7 alters the action of PAF (platelet-activating factor) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. PLA2G7 has specificity for substrates with a short residue at the sn-2 position. PLA2G7 is inactive against long-chain phospholipids.PLA2G7 gene defects are the source of platelet-activating factor acetylhydrolase deficiency, which is a trait that is present in 27% of the Japanese population.
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2009]
Uniprot Description
PLA2G7: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PAFAD). An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. Asthmatic individuals affected by this condition may manifest severe respiratory symptoms. Defects in PLA2G7 are a cause of susceptibility to asthma (ASTHMA). The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi. PLA2G7 variants can be a risk factor for the development of asthma and PLA2G7 may act as a modifier gene that modulates the severity of this disease. Defects in PLA2G7 are a cause of susceptibility to atopic hypersensitivity (ATOPY). A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. Belongs to the AB hydrolase superfamily. Lipase family.
Protein type: Lipid Metabolism - ether lipid; EC 3.1.1.47; Secreted, signal peptide; Hydrolase; Secreted
Chromosomal Location of Human Ortholog: 6p21.2-p12
Cellular Component: cytoplasm; extracellular region
Molecular Function: calcium-independent phospholipase A2 activity; phospholipid binding; 1-alkyl-2-acetylglycerophosphocholine esterase activity
Biological Process: cellular protein metabolic process; lipid catabolic process; positive regulation of inflammatory response
Disease: Asthma, Susceptibility To; Ige Responsiveness, Atopic; Platelet-activating Factor Acetylhydrolase Deficiency
Research Articles on PLA2G7
Similar Products
Product Notes
The PLA2G7 pla2g7 (Catalog #AAA145808) is a Recombinant Protein produced from HEK293 Cells and is intended for research purposes only. The product is available for immediate purchase. The amino acid sequence is listed below: FDWQYINPVA HMKSSAWVNK IQVLMAAASF GQTKIPRGNG PYSVGCTDLM FDHTNKGTFL RLYYPSQDND RLDTLWIPNK EYFWGLSKFL GTHWLMGNIL RLLFGSMTTP ANWNSPLRPG EKYPLVVFSH GLGAFRTLYS AIGIDLASHG FIVAAVEHRD RSASATYYFK DQSAAEIGDK SWLYLRTLKQ EEETHIRNEQ VRQRAKECSQ ALSLILDIDH GKPVKNALDL KFDMEQLKDS IDREKIAVIG HSFGGATVIQ TLSEDQRFRC GIALDAWMFP LGDEVYSRIP QPLFFINSEY FQYPANIIKM KKCYSPDKER KMITIRGSVH QNFADFTFAT GKIIGHMLKL KGDIDSNAAI DLSNKASLAF LQKHLGLHKD FDQWDCLIEG DDENLIPGTN INTTNQHIML QNSSGIEKYN VDHHHHH H. It is sometimes possible for the material contained within the vial of "Secreted Phospholipase A2-VII, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
